Home / Research library / MK-677
MK-677: molecular data, studies & sources
MK-677 is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C27H36N4O5S
- Molecular weight (MW)
- 528.7 g/mol
- PubChem compound ID
- 178024
- Record title
- Ibutamoren
Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.
Source: PubChem CID 178024 · retrieved 2026-09-21
Chemical identifiers and source data
- IUPAC name
- 2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide
- InChIKey
- UMUPQWIGCOZEOY-JOCHJYFZSA-N
- SMILES
- CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C(=O)N2CCC3(CC2)CN(C4=CC=CC=C34)S(=O)(=O)C)N
Identifiers
- PubChem CID
- 178024
- CAS Registry Number
- 159634-47-6via ChemIDplus, EPA DSSTox, FDA GSRS
- FDA UNII
- GJ0EGN38UL
- ChEMBL ID
- CHEMBL13817
- InChIKey
- UMUPQWIGCOZEOY-JOCHJYFZSA-N
Other names and development codes: L-163,191
CAS numbers are published only from ChemIDplus, EPA DSSTox or the FDA Global Substance Registration System; UNII codes are confirmed in FDA GSRS by structure, sequence or exact name. Checked 2026-10-07.
Calculated molecular descriptors
| Monoisotopic (exact) mass | 528.2406 Da |
|---|---|
| Heavy atoms | 37 |
| Hydrogen-bond donors | 2 |
| Hydrogen-bond acceptors | 6 |
| Rotatable bonds | 8 |
| Topological polar surface area | 122.0 Ų |
| Calculated logP (Crippen) | 1.77 |
| Rings | 4 |
| Stereocenters | 1 |
| Formal charge | 0 |
Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.
US regulatory status & drug development
Drugs@FDA lists no NDA, BLA or ANDA with ibutamoren as an active ingredient (names searched: IBUTAMOREN, IBUTAMOREN MESYLATE, MK-677; checked October 7, 2026). Research-labelled MK-677 listings are not FDA-approved drugs.
An FDA approval covers a defined medicine, formulation and labelled use. It does not extend to research-labelled material sold under the same compound name. Identity basis: INN ibutamoren, its mesylate and the code MK-677 were searched.
Source: Drugs@FDA via openFDA (active-ingredient search for IBUTAMOREN, IBUTAMOREN MESYLATE, MK-677) · checked . openFDA data are not intended for clinical decisions.
Drug development record (ChEMBL)
Harmonized drug-development record from ChEMBL. The highest clinical stage is the furthest stage reached, as recorded by ChEMBL; it can lag regulatory approvals, and it is not an approval of a research-supplier product.
- ChEMBL ID
- CHEMBL13817
- Modality
- Small molecule
- Highest clinical stage
- Phase 2
- Record name
- IBUTAMOREN
Synonyms, codes and trade names
- Synonyms and development codes
- Ibutamoren · L-163,191
Identity check: Identical standard InChIKey to the PubChem record. Source: ChEMBL CHEMBL13817 (EMBL-EBI, CC BY-SA 3.0) · retrieved 2026-10-07
Registered clinical trials
Studies registered on ClinicalTrials.gov that list Ibutamoren as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
4 registered studies matched, 1 with results posted on ClinicalTrials.gov.
- By highest phase
- Phase 2 · 3Not applicable · 1
- By registry status
- Completed · 3Withdrawn · 1
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 SubjectsNCT01343641 · start 2009-03 · primary completion 2010-04 | Phase 2WithdrawnWhy stopped: Could not obtain drug supply from manufacturer | Chronic Kidney Disease · Kidney Disease | University of VirginiaEnrollment not listed |
| Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD PatientsNCT00395291 · start 2006-08 · primary completion 2009-01 | Not applicableCompletedResults posted 2012-01-06 | Chronic Kidney Disease · End Stage Renal Disease | University of Virginia49 participants |
| Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of FibromyalgiaNCT00116129 · start 2005-07 · primary completion 2008-01 | Phase 2Completed | Fibromyalgia | Bennett, Robert, M.D.64 participants |
| Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older AdultsNCT00474279 · start 1998-07 | Phase 1 / Phase 2Completed | Aging | University of Virginia72 participants |
Registry check 2026-10-09 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received Ibutamoren, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
- Human study · PubMed trial index Compound given to participants
Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
Codner E, Cassorla F, Tiulpakov AN et al. · Clinical pharmacology and therapeutics · 2001
PMID 11452249 · DOI: 10.1067/mcp.2001.116514
- Human study · PubMed trial index Compound given to participants
MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.
Adunsky A, Chandler J, Heyden N et al. · Archives of gerontology and geriatrics · 2011
PMID 21067829 · DOI: 10.1016/j.archger.2010.10.004
- Human study · PubMed trial index Compound given to participants
Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.
Nass R, Pezzoli SS, Oliveri MC et al. · Annals of internal medicine · 2008
PMID 18981485 · DOI: 10.7326/0003-4819-149-9-200811040-00003
- Human study · PubMed trial index Compound given to participants
Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.
Sevigny JJ, Ryan JM, van Dyck CH et al. · Neurology · 2008
PMID 19015485 · DOI: 10.1212/01.wnl.0000335163.88054.e7
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
No additional matching publication was retained. The search links below allow further investigation; they are not evidence that a study exists.
MK-677 supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
MK-677 for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Cenexa LabsUSD | 15mg×60 Capsules1 recorded offers | 15mg×60 Capsules · $129.99Checked Nov 6, 2026Supplier listing, MK-677 15mg×60 Capsules, Cenexa Labs, opens in a new tab |
| Amino USAUSD | 25mg-per-mL-30mL Solution1 recorded offers | 25mg-per-mL-30mL Solution · $50.00Checked Nov 6, 2026Supplier listing, MK-677 25mg-per-mL-30mL Solution, Amino USA, opens in a new tab |
Reference sources & further reading
- PubChem compound record 178024 — chemical identity and structure.
- ChEMBL drug record CHEMBL13817 — development stage, mechanism and synonyms.
- FDA Global Substance Registration System: UNII GJ0EGN38UL — substance identity, names and codes.
- Wikipedia: Ibutamoren — Background encyclopedia; not a primary clinical source.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
Andarine (S4)
C19H18F3N3O6
441.4 g/mol · PubChem CID 9824562
5 selected publications · 0 human intervention studies
Cardarine
C21H18F3NO3S2
453.5 g/mol · PubChem CID 9803963
8 selected publications · 0 human intervention studies · 3 registered trials
Small molecule · highest stage: Phase 2
LGD-4033
C14H12F6N2O
338.25 g/mol · PubChem CID 44137686
8 selected publications · 1 human intervention study · 1 registered trial
Small molecule · highest stage: Phase 2
MK-777 (Acetamoren)
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Ostarine
C19H14F3N3O3
389.33 g/mol · ChEMBL CHEMBL1738889
8 selected publications · 0 human intervention studies · 17 registered trials
Small molecule · highest stage: Phase 3
RAD-140
C20H16ClN5O2
393.8 g/mol · PubChem CID 44200882
8 selected publications · 0 human intervention studies · 1 registered trial
Small molecule · highest stage: Phase 2